相关实验视频
Updated: Sep 16, 2025
08:50
Predictive Immune Modeling of Solid Tumors
Published on: February 25, 2020
7.1K
在免疫疗法时代,TTF-1阴性预测高级非状NSCLC的不良结果:多中心队列研究和元分析
Leonardo Brunetti1,2, Valentina Santo1, Alessandro Galletti1,3
1Department of Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, 200-00128 Rome, Italy.
Cancers
|July 12, 2025
概括
甲状腺转录因子-1 (TTF-1) 的消极性表明,接受免疫治疗的晚期非状NSCLC患者的预后不佳. 这种生物标志物对于个性化治疗策略至关重要,除了PD-L1表达之外.
科学领域:
- 在瘤学瘤学.
- 生物标志物研究 生物标志物研究
- 免疫治疗是一种免疫疗法.
背景情况:
- 需要可靠的生物标志物来指导高级非状NSCLC的免疫治疗决策.
- 甲状腺转录因子-1 (TTF-1) 在免疫疗法时代具有不清楚的预后价值.
- PD-L1表达是一种已确定的生物标志物,但需要额外的标志物.
研究的目的:
- 评估TTF-1表达在接受免疫治疗的晚期非状NSCLC的预后意义.
- 为了确定TTF-1状态是否可以在PD-L1表达之外细化治疗决策.
- 通过系统性审查和元分析,将发现与现有证据整合起来.
主要方法:
- 在163名先进非状NSCLC患者的多中心回顾性研究中,这些患者接受了第一线免疫疗法或化疗免疫疗法.
- 评估TTF-1表达的无进展生存期 (PFS) 和整体生存期 (OS).
- 按照PRISMA指南进行的9项研究 (14个队列,2019名患者) 的系统审查和元分析.
主要成果:
- TTF-1阴性与中位数PFS (6.7与16个月) 和OS (11.5与26.4个月) 的恶化显著相关.
- TTF-1的预后值独立于PD-L1状态;在TTF-1-阴性瘤中观察到PD-L1的有限预测相关性.
- 分析证实,TTF-1-阴性患者在免疫治疗方案中的结果明显较差 (PFS的HR合并: 1.75,OS: 1.76).
结论:
- TTF-1阴性独立地预测了以免疫疗法为基础的疗法治疗高级非状NSCLC的不良预后.
- TTF-1状态识别了免疫疗法受益有限的患者,即使PD-L1表达高.
- 将TTF-1集成到临床实践中可能会增强个性化治疗策略,从而证明未来的验证.
相关概念视频
01:27Tumor Immunotherapy
664
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
664
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K